<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003231</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 16/96</org_study_id>
    <secondary_id>SWS-SAKK-16/96</secondary_id>
    <secondary_id>EU-97034</secondary_id>
    <nct_id>NCT00003231</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug with surgery may kill more tumor
      cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with docetaxel
      and cisplatin followed by surgery in treating patients with stage IIIA non-small cell lung
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the efficacy and toxic effects of docetaxel plus cisplatin in patients
      with stage IIIA non-small cell lung cancer. II. Assess the clinical and pathological response
      rate to this therapy in this patient population. III. Compare the benefit of surgery in terms
      of overall survival of responding and nonresponding patients.

      OUTLINE: Patients receive infusions of docetaxel over 1 hour on day 1, followed by infusions
      of cisplatin over 1 hour on days 1-2. Treatment is repeated for three 21 day courses.
      Patients undergo tumor resection and mediastinal lymph node dissection. Patients are to
      receive postoperative radiotherapy within 4 weeks of resection if the tumor reaches the
      resection margins and/or the first mediastinal lymph node levels are involved. Patients will
      be followed until death.

      PROJECTED ACCRUAL: Approximately 5-40 patients will be accrued within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date type="Actual">September 2000</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven stage IIIA non-small cell lung cancer
        (NSCLC)(including squamous, adenocarcinoma, large cell, and poorly differentiated NSCLC)
        Nodal metastases of T1-3 N2 M0 No distant metastases

        PATIENT CHARACTERISTICS: Age: 18 to 75 Performance Status: WHO 0-2 Life Expectancy: Not
        specified Hematopoietic: Leucocytes greater than 4,000/mm3 Platelet count greater than
        100,000/mm3 Hepatic: Bilirubin within normal limits AST or ALT no greater than 1.5 times
        upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal:
        Creatinine clearance greater than 60 mL/min No hypercalcemia Cardiovascular: No unstable
        cardiac disease No congestive heart failure No angina pectoris No significant arrhythmias
        No prior history of myocardial infarction within 3 months Pulmonary: Lung function test
        with a forced expiratory volume greater than 1.2 L/sec Neurologic: No dementia No
        peripheral neuropathy greater than grade 1 No psychosis No seizure disorders Other: No
        prior or concurrent malignancies, except: Nonmelanoma skin cancer Carcinoma in situ of the
        cervix No active uncontrolled infection or other serious medical conditions No diabetes
        mellitus treated with insulin No gastric ulcers

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior chemotherapy Endocrine therapy: No prior corticosteroids or other endocrine therapy
        No concurrent treatment with prednisone (except for prophylaxis, treatment of acute
        hypersensitivity, or chronic treatment initiated greater than 6 months prior to study
        entry) Radiotherapy: No prior radiotherapy Surgery: No prior surgery for malignancy Other:
        No concurrent treatment with other experimental drugs No involvement in clinical trials
        within 30 days of study No prior treatment with other cytostatic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C. Betticher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Walter Weber-Stadelman</name>
      <address>
        <city>Basel</city>
        <zip>CH 4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burgerspital, Solothurn</name>
      <address>
        <city>Solothurn</city>
        <zip>4500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB; Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006 Apr 24;94(8):1099-106.</citation>
    <PMID>16622435</PMID>
  </results_reference>
  <results_reference>
    <citation>Betticher D, Hsu Schmitz S, Roth A, et al.: Neoadjuvant therapy with docetaxel and cisplatin in patients with non-small cell lung cancer (NSCLC), stage IIIA, pN2: a large phase II study with 59 months of follow-up. [Abstract] Lung Cancer 50 (Suppl 2): A-O-032, S14, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003 May 1;21(9):1752-9.</citation>
    <PMID>12721251</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2004</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

